drugset / Trial / NCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Tafasitamab | Monoclonal antibody | — | Intravenous |